Boehringer Ingelheim

Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners

Tuesday, May 11, 2021 - 1:00pm

"Our hope is that through these collective donations to our nonprofit partners, we will help make stronger and healthier communities where we live and work.

Key Points: 
  • "Our hope is that through these collective donations to our nonprofit partners, we will help make stronger and healthier communities where we live and work.
  • Since its founding in 1885, Boehringer Ingelheim is independent and family-owned.
  • In 2020, Boehringer Ingelheim achieved net sales of around 22.33 billion USD (19.57 billion EUR).
  • Please visit www.boehringer-ingelheim.us/csr to learn more about Corporate Social Responsibility initiatives.\nFor more information, please visit www.boehringer-ingelheim.us , or follow us on Twitter @BoehringerUS.\n'

DGAP-News: EVOTEC SE REPORTS RESULTS FOR THE FIRST QUARTER 2021 AND PROVIDES CORPORATE UPDATE

Tuesday, May 11, 2021 - 7:00am

We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.

Key Points: 
  • We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.
  • We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute).
  • Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
  • The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release.

Global HIV Drugs Market Report 2021: Long-term Forecast to 2025 & 2030 - ResearchAndMarkets.com

Friday, May 7, 2021 - 6:23pm

b'The "HIV Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nMajor players in the HIV drugs market are ViiV Healthcare, Gilead Sciences, Merck & Co., Inc., Bristol-Myers Squibb Company, Janssen (Johnson & Johnson), F. HOFFMANN-LA ROCHE LTD, Boehringer Ingelheim (C.H.

Key Points: 
  • b'The "HIV Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nMajor players in the HIV drugs market are ViiV Healthcare, Gilead Sciences, Merck & Co., Inc., Bristol-Myers Squibb Company, Janssen (Johnson & Johnson), F. HOFFMANN-LA ROCHE LTD, Boehringer Ingelheim (C.H.
  • HIV drugs are repurposed to treat Covid 19 infections.
  • Global HIV Drugs Historic Market, 2015-2020, $ Billion\n5.2.
  • Global HIV Drugs Forecast Market, 2020-2025F, 2030F, $ Billion\n'

Global Idiopathic Pulmonary Fibrosis Industry to 2029 - Opportunity Analysis and Forecasts - ResearchAndMarkets.com

Friday, May 7, 2021 - 11:45am

b'The "Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 (Event Driven Update)" report has been added to ResearchAndMarkets.com\'s offering.\nIdiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs).

Key Points: 
  • b'The "Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 (Event Driven Update)" report has been added to ResearchAndMarkets.com\'s offering.\nIdiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs).
  • Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis.
  • However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule treatments; Roche\'s Esbriet and Boehringer Ingelheim\'s Ofev.
  • Insightful review of the key industry drivers, restraints and challenges.

BearingPoint client success story: Boehringer Ingelheim increases data accuracy by leveraging robotic process automation

Thursday, May 6, 2021 - 9:05am

Boehringer Ingelheim now has a more efficient material verification process, with an automated execution and the lowest risk of human errors.\nManagement and technology consultancy BearingPoint worked with Boehringer Ingelheim in gathering data from each manual step involved in the storage process by using UiPath\xe2\x80\x99s Task Capture\xc2\xae.

Key Points: 
  • Boehringer Ingelheim now has a more efficient material verification process, with an automated execution and the lowest risk of human errors.\nManagement and technology consultancy BearingPoint worked with Boehringer Ingelheim in gathering data from each manual step involved in the storage process by using UiPath\xe2\x80\x99s Task Capture\xc2\xae.
  • A Process Definition Document was created, with a detailed As-Is and To-Be process description.
  • BearingPoint transferred the current manual methodology into a master file template, making it easy to adapt to potential changes, and providing data for a bot to read.
  • The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success.

DGAP-News: Evotec SE to announce results for the first quarter 2021 on 11 May 2021

Tuesday, May 4, 2021 - 11:28am

We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.

Key Points: 
  • We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.
  • We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute).
  • Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
  • The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release.

Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes

Monday, May 3, 2021 - 1:00pm

20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that Diabetes Care has published results from its Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes.

Key Points: 
  • 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that Diabetes Care has published results from its Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes.
  • In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may produce hypoglycemia.
  • More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market.
  • License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Worldwide Neurological Diseases Treatment Industry to 2029 - Featuring Novartis, GlaxoSmithKline and Bayer Among Others

Friday, April 30, 2021 - 5:00pm

b'DUBLIN, April 30, 2021 /PRNewswire/ -- The "Neurological Diseases Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nThis report offers strategic insights into the overall neurological diseases treatment market along with the market size and estimates for the duration 2019 to 2029.

Key Points: 
  • b'DUBLIN, April 30, 2021 /PRNewswire/ -- The "Neurological Diseases Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nThis report offers strategic insights into the overall neurological diseases treatment market along with the market size and estimates for the duration 2019 to 2029.
  • The said research study cover in-depth analysis of neurological treatment market segments based on type of drugs, diseases and different geographies further segmented by countries.\nFor the purpose of this study, the global neurological diseases treatment market is segmented on the basis of drug type into anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others.
  • Market size and forecast for these segments during 2019 to 2029 and their CAGRs for the period 2021 to 2029 are provided in this report.\nThe neurological diseases treatment market is observed as the most diversified and competitive market comprising large number of players.
  • The key players in this market are Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc among others.\nBased on the type of drug, the global neurological diseases treatment market is segmented as follows:\n'

Total number of shares and voting rights in Zealand Pharma at April 30, 2021

Thursday, April 29, 2021 - 3:29pm

More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market.

Key Points: 
  • More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market.
  • Zealand\xe2\x80\x99s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States.
  • License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.\n'

Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands Scientific Advisory Team

Tuesday, April 27, 2021 - 1:00pm

As a Key Opinion Leader studying Alzheimer\xe2\x80\x99s disease, Krista\xe2\x80\x99s work focuses on cognitive and neuropsychiatric symptoms associated with dementia.

Key Points: 
  • As a Key Opinion Leader studying Alzheimer\xe2\x80\x99s disease, Krista\xe2\x80\x99s work focuses on cognitive and neuropsychiatric symptoms associated with dementia.
  • Previously, Dr. Duan spent more than 20 years at Boehringer Ingelheim (Canada) Ltd. in roles of increasing responsibility, most recently as Director, Preclinical ADMEPK/Pharmacology.
  • Before joining Bright Minds, Mr. Grizzle was a successful consultant, advising clients across these critical domains and helping them achieve successful outcomes.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.